Glycanage Ltd Secures £566k Funding to Advance Biological Age Testing

Glycanage Ltd, a Newcastle upon Tyne-based biotechnology company specialising in biological age testing, has successfully secured £566,000 in a recent funding round. The capital infusion, with an allotment date of April 2, 2026, and filing date of April 6, 2026, is set to bolster the company's efforts in expanding its innovative preventative healthcare solutions.

Founded in 2016, Glycanage Ltd addresses the critical need for deeper insights into the aging process and associated health risks. The company offers a proprietary biological age test that analyses glycans in blood samples to measure chronic inflammation. This approach provides individuals and healthcare providers with actionable data on how lifestyle, chronic inflammation, and environmental factors influence biological age, moving beyond traditional chronological age measurements.

With a team of 45 employees, Glycanage Ltd operates within the biotechnology research industry, leveraging over 30 years of research and more than 300 peer-reviewed publications to underpin its technology. Its flagship GlycanAge® test is currently utilised by over 1,500 providers and tens of thousands of customers globally, primarily within preventive and longevity clinics. The company is actively expanding its reach into hospital settings and the direct-to-consumer market, with specific applications targeting cardiometabolic health and menopausal diagnostics for personalised preventative healthcare. While specific revenue and profit/loss figures for Glycanage Ltd were not disclosed, the company's growth in customer base and market expansion indicate a strong operational trajectory.

This latest funding round saw Glycanage Ltd raise £566,000. The valuation of the company at the time of this round has not been publicly disclosed, nor have the specific investors involved. This new capital adds to previously reported total funding for Glycanage. In August 2024, the company was noted as one of the "best funded of the UK longevity startups" having secured approximately £3.7 million (equivalent to $4.7 million at the time) in total funding to that point. This latest round signifies continued investor confidence in Glycanage's mission and technology.

The funding round for Glycanage Ltd occurs within a dynamic UK funding landscape for biotechnology and preventative healthcare. The broader UK biotech sector experienced a challenging investment climate in 2025, yet concluded the year with renewed momentum and increased investor confidence, particularly in the final quarter. Despite a 13.2% year-on-year decrease in venture capital investment to £1.79 billion across 58 deals in 2025, the UK maintained its position as Europe's leading national biotech market, accounting for 30% of all European venture financing. However, funding was largely concentrated in a few significant rounds, leading to a higher average deal size of £30.8 million, while mid-sized scale-up financings remained constrained. Glycanage's £566,000 round, while smaller than the average, contributes to the overall deal activity and reflects ongoing investment in promising early to growth-stage companies.

Within the longevity technology sector, the global market is experiencing substantial growth, valued at an estimated US$27 billion in 2023 and projected to reach US$45 billion by 2031. Global investment in longevity companies more than doubled in 2024, reaching US$8.49 billion. While the US currently dominates this space, the UK possesses strong foundations in longevity research and is striving to become a leading hub, despite facing a funding gap compared to its American counterparts. Glycanage's focus on biological aging positions it squarely within this expanding and strategically important market.

Furthermore, the UK is increasingly prioritising preventative healthcare, with the NHS and government advocating for a shift towards prevention-first health systems. The UK's digital health sector is robust, with startups valued at £32 billion by the end of 2024, having collectively raised £27.4 billion in capital. Companies like Glycanage, offering at-home tests and personalised insights, align with the growing demand for accessible and proactive health management tools. This strategic alignment with national healthcare priorities and a burgeoning market positions Glycanage Ltd for continued relevance and growth.

This latest funding round will enable Glycanage Ltd to further its mission of empowering individuals with actionable insights into their biological age, contributing to healthier and longer lives through personalised preventative healthcare.